HSV-1 and -2 serology for the 2 groups was evaluated at HIV diagnosis and longitudinally for those with ≥1 year of follow-up.
BioPlex HSV (Bio-Rad Laboratories, Benecia, CA) is the current HSV assay and has been used in our facility since 2010. ICD-9 codes for genital herpes after HIV diagnosis were also examined to evalu-ate the clinical impact of HSV-1 and -2 seropositivity. As a marker for ongoing high-risk sexual behaviors, ICD-9 codes for STIs, includ-ing gonorrhea, chlamydia, and syphilis, and HSV-2 seroconversions were captured for those with ≥1 year of follow-up after HIV diag-nosis. HSV serostatus and prevalence of both HSV and non-HSV STIswere compared between groups by chisquared test and odds ratios were calculated using IBM SPSS Statistics 22.0, Chicago, Illinois.